Clinical Trial Update: The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating 3% trehalose ophthalmic solution for corneal epithelial barrier function in dry eye disease; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• Trehalose Ophthalmic Solution 3% (trehalose ophthalmic solution)

Snippet

Sponsor: Southern California College of Optometry at Marshall B. Ketchum University | Conditions: Dry Eye Disease (DED) | Phase 4 | Status: NOT_YET_RECRUITING